Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and TTI-622 in Relapsed/Refractory DLBCL
NCT05507541Phase 2Active, not recruiting
- Sponsor
- Mayo Clinic
- Start
- Apr 2023
- Primary completion
- Jul 2027
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of maplirpacept in diffuse large B-cell lymphoma (DLBCL), sponsored by Mayo Clinic. Started Apr 2023; status: active, not recruiting.
02
Drugs
maplirpacept
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05507541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05507541.